IL326139A - טיפול בסרטן עם מעכב cdk - Google Patents

טיפול בסרטן עם מעכב cdk

Info

Publication number
IL326139A
IL326139A IL326139A IL32613926A IL326139A IL 326139 A IL326139 A IL 326139A IL 326139 A IL326139 A IL 326139A IL 32613926 A IL32613926 A IL 32613926A IL 326139 A IL326139 A IL 326139A
Authority
IL
Israel
Prior art keywords
amino
triazin
oxan
cancer
pyrrolo
Prior art date
Application number
IL326139A
Other languages
English (en)
Original Assignee
Khora Spv 1 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khora Spv 1 Llc filed Critical Khora Spv 1 Llc
Publication of IL326139A publication Critical patent/IL326139A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326139A 2023-07-26 2024-07-25 טיפול בסרטן עם מעכב cdk IL326139A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363515752P 2023-07-26 2023-07-26
US202463554735P 2024-02-16 2024-02-16
PCT/US2024/039552 WO2025024665A1 (en) 2023-07-26 2024-07-25 Treatment of cancer with a cdk inhibitor

Publications (1)

Publication Number Publication Date
IL326139A true IL326139A (he) 2026-03-01

Family

ID=94375747

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326139A IL326139A (he) 2023-07-26 2024-07-25 טיפול בסרטן עם מעכב cdk

Country Status (5)

Country Link
EP (1) EP4750476A1 (he)
KR (1) KR20260087576A (he)
AU (1) AU2024301095A1 (he)
IL (1) IL326139A (he)
WO (1) WO2025024665A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533939A (ja) * 2019-05-17 2022-07-27 キネート バイオファーマ インク. 線維芽細胞増殖因子受容体キナーゼの阻害剤
AU2023212957A1 (en) * 2022-01-25 2024-08-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase

Also Published As

Publication number Publication date
WO2025024665A1 (en) 2025-01-30
KR20260087576A (ko) 2026-06-11
AU2024301095A1 (en) 2026-03-12
EP4750476A1 (en) 2026-06-03

Similar Documents

Publication Publication Date Title
EP4326256A4 (en) Treating cancer with a RAF inhibition
IL315996A (he) טיפולים בסרטן באמצעות מעכבי prmt5 בשיתוף mta
IL316829A (he) מעכבי מנין-mll לטיפול בסרטן
IL321326A (he) טיפולי סרטן באמצעות מעכבי prmt5 משתפים פעולה עם mta
IL312650A (he) מעכב cdk4 לטיפול בסרטן
IL326327A (he) טיפול בסרטן הערמונית
CA3310959A1 (en) Treatment of cancer with a parg inhibitor
IL314687A (he) טיפול בסרטן
CA3289173A1 (en) Treatment of cancer with a met kinase inhibitor
GB202311976D0 (en) Treatment of cancer
GB202218181D0 (en) Treatment of cancer
GB202201803D0 (en) Treatment of Cancer
HK40072722A (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
CA3294486A1 (en) Combination therapy with mek inhibitors for the treatment of cancer
IL320448A (he) שיטות לטיפול בסרטן באמצעות סוטורסיב
HK40120366A (zh) 癌症的治疗
AU2021903147A0 (en) A method of treating cancer
HK40079140A (en) Combination cancer therapy using chk inhibitor
HK40079139A (en) Combination cancer therapy using chk inhibitor
AU2021901530A0 (en) Treatment of a hydro-excavated mud
CA3250741A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNITIES
GB202018062D0 (en) Treatment of cancer
CA3270268A1 (en) Methods of treating cancer with sotorasib
HK40093441A (en) Use of a dhodh inhibitor compound in combination cancer therapy
HK40091391A (en) Use of a dhodh inhibitor compound in combination cancer therapy